Dyne Therapeutics Inc (NAS:DYN)

$ 30.61 -0.52 (-1.67%) Market Cap: 3.12 Bil Enterprise Value: 2.42 Bil PE Ratio: 0 PB Ratio: 4.41 GF Score: 40/100

Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Dyne Therapeutics Inc ACHIEVE and DELIVER Clinical Data Update Transcript
Jan 03, 2024
Dyne Therapeutics Inc at Jefferies CNS & Neuro Summit Transcript
Oct 12, 2023
Dyne Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
Oct 03, 2023
Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Dyne Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Dyne Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Dyne Therapeutics Inc Advancing FORCE in the Pursuit of Transformative Therapies Transcript
May 03, 2023
Dyne Therapeutics Inc Meet the DM Drug Developers 2023 Transcript
Apr 07, 2023
Dyne Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 04, 2023
Dyne Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Mar 29, 2023
Dyne Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Dyne Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Dyne Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Dyne Therapeutics Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Dyne Therapeutics Inc at Chardan Genetic Medicines Conference Transcript
Oct 04, 2022
Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Dyne Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Dyne Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
Dyne Therapeutics Inc Industry Updates Friday Transcript
Oct 06, 2020

Dyne Therapeutics Inc ACHIEVE and DELIVER Clinical Data Update Transcript

Jan 03, 2024 / 01:00PM GMT

Release Date Price: $14.77 (+13.09%)

Transcript

Amy Reilly Dyne Therapeutics Inc.;SVP

Head of Corporate Communications & IR

Good morning, everyone, and Amy Reilly, Senior Vice President, Head of Corporate Communications, and Investor Relations at Dyne. Thank you for joining us for Dyne's virtual event, achieving the promise of force to deliver for patients. Today, we will be presenting Dyne's very first clinical data from our DYNE-101 ACHIEVE Trial in myotonic dystrophy type 1 and our DYNE-251 DELIVER trial in Duchenne muscular dystrophy, which we summarized in the press release issued earlier today.

Before we begin, I'd like to remind everyone that we will be making forward-looking statements today that are subject to the Safe Harbor protections provided under the Private Securities Litigation Reform Act of 1990. Actual results may differ materially from these forward-looking statements as a result of various important factors including those discussed in the risk factors section of our recent 10-Q. These statements represent our views as of today's date, and we disclaim any obligation to update these statements.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.